A method for improving body shape and improving skin condition using a noni fruit ferment is provided, and the method includes: administrating a composition to a subject in need thereof. The composition includes an effective amount of noni fruit ferment. The noni fruit ferment is prepared by (a) mixing glucose and noni fruit with water for extraction, to obtain a noni fruit broth, and (b) fermenting the noni fruit broth with a plurality of bacteria strains. The bacteria strains include yeast, lactic acid bacteria, and acetic acid bacteria. In step (b), the noni fruit broth and the bacteria strains are irradiated with a red light source with a wavelength of 620 nm to 750 nm. In addition, the noni fruit ferment also has at least one of the following functions: removing free radicals, improving defecation status, and improving gastrointestinal motility.

A method for improving body shape and improving skin condition using a noni fruit ferment is provided, and the method includes: administrating a composition to a subject in need thereof. The composition includes an effective amount of noni fruit ferment. The noni fruit ferment is prepared by (a) mixing glucose and noni fruit with water for extraction, to obtain a noni fruit broth, and (b) fermenting the noni fruit broth with a plurality of bacteria strains. The bacteria strains include yeast, lactic acid bacteria, and acetic acid bacteria. In step (b), the noni fruit broth and the bacteria strains are irradiated with a red light source with a wavelength of 620 nm to 750 nm. In addition, the noni fruit ferment also has at least one of the following functions: removing free radicals, improving defecation status, and improving gastrointestinal motility.

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT.sub.2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D.sub.1/D.sub.2 receptor signaling systems, and/or the treatment of residual symptoms.

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.